Renal function in type 2 diabetes with rosiglitazone,metformin, and glyburide monotherapy

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 5, 2011, Pages 1032-1040

  Lachin, John M ^a   Viberti, Giancarlo ^b   Zinman, Bernard ^c   Haffner, Steven M ^d   Aftring, R Paul ^e   Paul, Gitanjali ^e   Kravitz, Barbara G ^e   Herman, William H ^f   Holman, Rury R ^g   Kahn, Steven E ^h  

^a Biostatistics Center   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MOUNT SINAI HOSPITAL   (Canada)

^d GlaxoSmithKline ^*

^e UNIVERSITY OF MICHIGAN   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^h GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; GLIBENCLAMIDE; METFORMIN; ROSIGLITAZONE;

ADULT; AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; ALBUMINURIA; BLOOD GLUCOSE; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 79957824748     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.09291010     Document Type: Article

References (34)

1. Karalliedde J, Viberti G: Microalbuminuria and cardiovascular risk. Am J Hypertens 17: 986-993, 2004
2. Diabetes Control and Complications Trial (DCCT) Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group. Kidney Int 47: 1703-1720. 1995
3. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589, 2008
4. Wang PH, Lau J, Chalmers TC: Meta-analysis of effects of intensive blood glucose control on late complications of type 1 diabetes. Lancet 341: 1306-1309, 1993
5. Guan Y, Breyer MD: Peroxisome proliferator-activated receptors (PPARs): Novel therapeutic targets in renal disease. Kidney Int 60: 14-30, 2001
6. Isshiki K, Haneda M, Koya D, Maeda S, Sugimoto T, Kikkawa R: Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49: 1022-1032, 2000
7. Miyazaki Y, Cersosimo E, Triplitt C, DeFronzo RA: Rosiglitazone decreases albuminuria in type 2 diabetic patients. Kidney Int 72: 1367-1373, 2007
8. Viberti G, Kahn SE, Greene DA, Herman WH, Zinman B, Holman RR, Haffner SM, Levy D, Lachin JM, Berry RA, Heise MA, Jones NP, Freed MI: A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 25: 1737-1743, 2002
9. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443, 2006
10. Levey A, Bosch J, Breyer Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine. Ann Intern Med 139: 461-470, 1999
11. Snedecor GW, Cochran WG: Statistical Methods, 7th ed., Ames, Iowa, Iowa State University Press, 1980
12. Neter J, Kutner MH, Nachtsheim CJ, Wasserman W: Applied Linear Statistical Models, Chicago, Irwin, 1996
13. Demidenko E: Mixed Models: Theory and Applications, New York, John Wiley & Sons, 2006
14. Kalbfleisch JD, Prentice RL: The Statistical Analysis of Failure Time Data, 2nd ed., New York, John Wiley & Sons, 2002
15. Hochberg Y: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75: 800-802, 1988
16. Gaede P, Lund-Andersen H, Parving HH, Pedersen O: Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358: 580-591, 2008
17. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators: Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941-1951. 2004
18. Wolf G, Ritz E: Diabetic nephropathy in type 2 diabetes prevention and patient management. J Am Soc Nephrol 14: 1396-1405, 2003
19. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators: Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressure-independent effect. Circulation 106: 672-678, 2002
20. Amador-Licona N, Guízar-Mendoza J, Vargas E, Sánchez-Camargo G, Zamora-Mata L: The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus. Arch Med Res 31: 571-575, 2000
21. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN: Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: A meta-analysis. Am J Kidney Dis 55: 835-847, 2010
22. Zheng F, Guan Y: Thiazolidinediones: A novel class of drugs for the prevention of diabetic nephropathy? Kidney Int 72: 1301-1303, 2007
23. Yosefy C, Magen E, Kiselevich A, Priluk R, London D, Volchek L, Viskoper RJ Jr: Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 44: 215-222, 2004
24. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 17: 7-12, 2003
25. Sarafidis PA, Lasaridis AN, Nilsson PM, Pagkalos EM, Hitoglou-Makedou AD, Pliakos CI, Kazakos KA, Yovos JG, Zebekakis PE, Tziolas IM, Tourkantonis AN: Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004; 22: 1769-1777, 2004
26. Komajada M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R. Home PD; RECORD study group. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled study (the RECORD study). Cardiovasc Diabetol 7: 10, 2008
27. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, Porter LE: Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 24: 2047-2055, 2006
28. Glassock RJ: Estimated glomerular filtration rate: Time for a performance review? Kidney Int 75: 1001-1003, 2009
29. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG: Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52: 691-697, 2009
30. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 290: 2159-2167, 2003
31. Holman RR, Paul SK, Bethel MA, Neil HA, Matthews DR: Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359: 1565-1576, 2008
32. Dluhy RG, McMahon GT: Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med 358: 2630-2633, 2008
33. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360: 129-139, 2009
34. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358: 2560-2572, 2008